Scholars Central

Review articlePublished 22 Jul 2016

Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease

Authors: P Claudio, N Annunziata, S Mega, R Melfi & DS Germano

Interventional Cardiology

Volume 7 · Issue 3 · Pages 283–294

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diabetes mellitus is characterized by enhanced platelet reactivity and impaired response to antiplatelet therapy, with a higher percentage of low responders and an increased risk of thrombotic events following an acute coronary syndrome and/or percutaneous coronary intervention. This evidence was utilized to investigate the effectiveness and safety of higher doses of clopidogrel as well as the use of newer and more potent antiplatelet drugs, such as prasugrel and ticagrelor, in this highrisk subset of patients. The aim of this paper is to systematically report the latest evidence on the prognostic role of diabetes mellitus on responsiveness to antiplatelet treatments and to discuss the most effective therapeutic strategy to be used in such patients.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Interventional Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInterventional Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “P Claudio”
  • BylineArticles whose byline prints “N Annunziata”
  • BylineArticles whose byline prints “S Mega”
  • BylineArticles whose byline prints “R Melfi & DS Germano”